|
Median age at HCT, years (range)
|
56 (21–77)
|
|
Male gender
|
150 (60)
|
|
Race
|
|
Caucasian
|
214 (86)
|
|
African American
|
5 (2)
|
|
Othersa
|
17 (7)
|
|
Missing
|
13 (5)
|
|
Karnofsky performance score ≥ 90
|
119 (48)
|
|
< 90
|
113 (45)
|
|
Missing
|
17 (7)
|
|
HCT-CI
|
|
0
|
46 (18)
|
|
1–2
|
53 (21)
|
|
≥ 3
|
84 (34)
|
|
Not available before 2007
|
55 (22)
|
|
Missing
|
11 (4)
|
|
Interval from diagnosis to HCT, months
|
|
Median (range)
|
14 (3–118)
|
|
Median lines of therapy before HCT (range)
|
3 (1–5)
|
|
Remission status at HCT
|
|
Complete remission
|
108 (43)
|
|
Partial remission
|
90 (36)
|
|
Chemorefractory
|
38 (15)
|
|
Untreated/unknown
|
13 (5)
|
|
History of prior autologous HCT
|
98 (39)
|
|
TBI in conditioning
|
83 (34)
|
|
ATG/alemtuzumab in conditioningb
|
59 (24)
|
|
Conditioning intensityc
|
|
Myeloablative conditioning
|
66 (27)
|
|
Non-myeloablative/RIC
|
183 (73)
|
|
Graft source
|
|
Bone marrow
|
8 (3)
|
|
Peripheral blood
|
241 (97)
|
|
Donor type
|
|
HLA-identical sibling
|
140 (56)
|
|
Unrelated donor 8/8
|
109 (44)
|
|
Donor/recipient CMV status
|
|
Both negative
|
72 (29)
|
|
Both positive
|
59 (24)
|
|
Either donor/recipient +
|
69 (28)
|
|
Missing
|
49 (19)
|
|
Graft-versus-host disease prophylaxis
|
|
Calcineurin inhibitor + MTX ± othersd (except MMF)
|
119 (48)
|
|
Calcineurin inhibitor + MMF ± othersd
|
76 (31)
|
|
Calcineurin inhibitor + others (except MMF)
|
40 (16)
|
|
Othersd
|
10 (4)
|
|
Missing
|
4 (2)
|
|
Year of HCT
|
|
2000–2006
|
47 (19)
|
|
2007–2011
|
82 (33)
|
|
2012–2016
|
120 (48)
|
|
Median follow-up of survivors (range), months
|
49 (4–170)
|
